ImmunoBiochem Corporation

Technology
ImmunoBiochem is developing potentiated biologics targeted at novel tumor antigens that are augmented in cancer cell secretomes and accumulate in the tumor microenvironment. This targeting approach overcomes the challenges of solid tumor heterogeneity and tumor penetration by antibodies. ImmunoBiochem is able to deliver novel immunomodulatory payloads to a variety of cell types within the tumor in a highly selective fashion, pioneering a next-generation strategy for the delivery of innate immune system modulators.
READ MORE
Pipeline
ImmunoBiochem pipeline consists of several biologics for oncology aiming to solve the problem of tumor heterogeneity. The lead candidates, IMB-212, IMB-213I and IMB-214R, are in development for a number of difficult-to-treat solid malignancies, including rare, orphan disease.
READ MORE
About
ImmunoBiochem Corporation is committed to developing novel, targeted biological therapeutics for oncology.
READ MORE

IMB-213I

IMB-213I is a novel antibody carrying a potent immunomodulatory payload aimed at the innate immune system. IMB-213I is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-213I is based on ImmunoBiochem's proprietary technology platform that enables it to target select secreted proteins amplified in the tumor microenvironment and possessing unique tumor biology. IMB-213I designed for the selective and efficacious delivery of its immunomodulatory payload to important immune cells within the tumor and tumor stroma, differentiating it from most other antibodies carrying immunomodulatory payloads in development that are aimed at surface-expressed tumor targets for delivery of such payload into tumor cells.

IMB-212

IMB-212 is a novel antibody-drug conjugate that is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-212 is based on ImmunoBiochem's proprietary technology platform that enables it to target select secreted proteins amplified in the tumor microenvironment and possessing unique tumor biology. This targeting approach overcomes the challenges of solid tumor heterogeneity and tumor penetration by antibodies. IMB-212 carries a clinically-proven cytotoxic payload and is currently at the preclinical stage of development.

News

12-4-2018
ImmunoBiochem has attended RESI in Toronto for investor meetings and exhibited at The Future of Health Innovation during the Toronto Health Innovation Week (THIW)
The Future of Health Innovation at MaRS Discovery District
ImmunoBiochem's CEO, Anton Neschadim, speaking at the RESI "Tales from the Road" CEO Panel